Name the material precisely
Record the sequence or molecular identifier, relevant terminal modifications, salt or counterion, formulation and combination ingredients. Then compare those details with the methods section of the cited study.
These are not administrative details. A shortened fragment, a modified analogue and a full-length molecule may have different properties even when they share part of a name. A blend adds further questions about amounts, interactions and stability.
The TB-500 example
A primary analytical study identified an acetylated seven-amino-acid thymosin beta-4 fragment in an examined TB-500 product. That finding is not proof that every product called TB-500 is the same fragment or that it is equivalent to full-length thymosin beta-4.
The TB-500 guide keeps identity evidence distinct from human efficacy claims. An authentic paper about one material does not resolve the contents or biological behavior of every similarly named vial.
A simple identity worksheet
Use one row per material rather than combining several names into a single unqualified record.
| Field | Example question |
|---|---|
| Exact name or identifier | Is this a brand, chemical entity or family? |
| Sequence or structure | Does the paper specify the same molecule? |
| Modifications | Are terminal groups or substitutions different? |
| Formulation | Are solvent, excipients and concentration comparable? |
| Combination | Are the same components and amounts present? |
| Exposure | Was the same route studied? |
Keep unresolved identity visible
If the available documents do not resolve a match, describe the comparison as unresolved. Do not choose whichever identity makes the advertised evidence look strongest.
For KLOW, ingredient documentation is separated from component studies. For SLU-PP-332, the guide identifies a small molecule rather than calling it a peptide. Consistent naming makes the evidence library searchable without pretending that related entities are interchangeable.